Data MATRIX Introduces an AI-Operated Patient Survival Assessment Tool

Data MATRIXData MATRIX, a sole Real-World Evidence solutions provider in Russia, has presented a predictive analytics tool for estimating patient survival based on Real-World Data.

An important feature of the presented tool for predictive analysis of Real-World Data is its countrywide potential, and the ability to collect and analyze data on different patient cohorts. That in turn allows the estimation of the survival of a patient based on their individual parameters and performed or planned treatment, before being compared with the best treatment option for similar baseline data. Machine algorithms collect information about patients from medical records received from prevention and treatment facilities, pharmaceutical companies, and researchers in 29 regions of the Russian Federation.

The tool demonstration took place at Skolkovo Innovation Center with the participation of the Russian Ministry of Health, and the Russian Ministry of Economic Development. The event was also attended by representatives of major international and Russian pharmaceutical manufacturers such as Novartis, Janssen, and R-Pharm.

The company's medical director, Polina Shpigotskaya, held a live demonstration of the tool's capabilities to the participants, using breast cancer patients as an example. However, the product is also suitable for other therapeutic areas. In real time, the system processed the information about cancer patients with specified parameters, such as sex, age, degree of malignancy, and menopause status, and displayed in graphs and excel tables the prognosis of survival with the best treatment option for the cohort. The company plans to expand the functionality of the platform, increase the database through partnerships with medical institutions, and scale up the system throughout the Russian Federation.

The event was preceded by Russian President’s Vladimir Putin signing Federal Law which established a regulatory sandbox for 7 digitally innovative projects. Data MATRIX was among the 7 projects that can operate within this legal regime. Under the law, Data MATRIX can process personal data derived from electronic healthcare records (EHRs) in an anonymized form. The company will be able to conduct retrospective clinical studies without signing informed consent and obtain anonymized data from healthcare facilities and data integrators.

As a result, pharmaceutical and biotech companies will have a legally compliant provider of Real-world data (RWD) derived from millions of EHRs. This will contribute to the overall knowledge base on drugs efficacy and safety, including those of vaccines.

For further information, please visit:
https://dm-matrix.com

About Data MATRIX

Data MATRIX RWE offers a wide range of Real World Evidence (RWE) solutions with access to millions of electronic health records. This start-up also delivers clinical data management and biostatistics services and develops software for clinical research. To date, the DM RWE portfolio includes over 200 projects for pharmaceutical and biotechnology companies and CROs. DM RWE products include applications such as EDC, IWRS and ePRO. The company is a member of CDISC, ACDM, SCDM and other professional communities.

Most Popular Now

AI also Assesses Dutch Mammograms Better…

AI is detecting tumors more often and earlier in the Dutch breast cancer screening program. Those tumors can then be treated at an earlier stage. This has been demonstrated by...

RSNA AI Challenge Models can Independent…

Algorithms submitted for an AI Challenge hosted by the Radiological Society of North America (RSNA) have shown excellent performance for detecting breast cancers on mammography images, increasing screening sensitivity while...

AI could Help Emergency Rooms Predict Ad…

Artificial intelligence (AI) can help emergency department (ED) teams better anticipate which patients will need hospital admission, hours earlier than is currently possible, according to a multi-hospital study by the...

Head-to-Head Against AI, Pharmacy Studen…

Students pursuing a Doctor of Pharmacy degree routinely take - and pass - rigorous exams to prove competency in several areas. Can ChatGPT accurately answer the same questions? A new...

NHS Active 10 Walking Tracker Users are …

Users of the NHS Active 10 app, designed to encourage people to become more active, immediately increased their amount of brisk and non-brisk walking upon using the app, according to...

Unlocking the 10 Year Health Plan

The government's plan for the NHS is a huge document. Jane Stephenson, chief executive of SPARK TSL, argues the key to unlocking its digital ambitions is to consider what it...

AI can Find Cancer Pathologists Miss

Men assessed as healthy after a pathologist analyses their tissue sample may still have an early form of prostate cancer. Using AI, researchers at Uppsala University have been able to...

How AI could Speed the Development of RN…

Using artificial intelligence (AI), MIT researchers have come up with a new way to design nanoparticles that can more efficiently deliver RNA vaccines and other types of RNA therapies. After training...

AI, Full Automation could Expand Artific…

Automated insulin delivery (AID) systems such as the UVA Health-developed artificial pancreas could help more type 1 diabetes patients if the devices become fully automated, according to a new review...

MIT Researchers Use Generative AI to Des…

With help from artificial intelligence, MIT researchers have designed novel antibiotics that can combat two hard-to-treat infections: drug-resistant Neisseria gonorrhoeae and multi-drug-resistant Staphylococcus aureus (MRSA). Using generative AI algorithms, the research...

AI Hybrid Strategy Improves Mammogram In…

A hybrid reading strategy for screening mammography, developed by Dutch researchers and deployed retrospectively to more than 40,000 exams, reduced radiologist workload by 38% without changing recall or cancer detection...

Penn Developed AI Tools and Datasets Hel…

Doctors treating kidney disease have long depended on trial-and-error to find the best therapies for individual patients. Now, new artificial intelligence (AI) tools developed by researchers in the Perelman School...